| value |
{"aggregator_url":"https://news.google {"aggregator_url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5oREVnNnhiZm1vQmpzbVdNLXlIQ01hWDFoLXdqM05obVhOclJJTWoxOTlkY3dMTk9HdDJBV1RhaFpYZG9Ya3I2Qm9FMktwUlhsWldv?oc=5","as_of":"2026-04-09T22:59:43.472613+00:00","canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","enrichment":{"aggregator_url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5oREVnNnhiZm1vQmpzbVdNLXlIQ01hWDFoLXdqM05obVhOclJJTWoxOTlkY3dMTk9HdDJBV1RhaFpYZG9Ya3I2Qm9FMktwUlhsWldv?oc=5","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_1eef5a68681ec41b","canonical_host":"gstatic.com","canonical_is_aggregator":true,"canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-10T02:47:55.644133+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5oREVnNnhiZm1vQmpzbVdNLXlIQ01hWDFoLXdqM05obVhOclJJTWoxOTlkY3dMTk9HdDJBV1RhaFpYZG9Ya3I2Qm9FMktwUlhsWldv?oc=5&hl=en-US&gl=US&ceid=US:en","html_truncated":true,"paywall_likely":false,"publisher_domain":"gstatic.com","publisher_resolution":"canonical_aggregator_unresolved","requested_url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5oREVnNnhiZm1vQmpzbVdNLXlIQ01hWDFoLXdqM05obVhOclJJTWoxOTlkY3dMTk9HdDJBV1RhaFpYZG9Ya3I2Qm9FMktwUlhsWldv?oc=5","source_event_id":"evt_584c61f84701","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"be511b9b02d4bccf","kind":"ipo_calendar","published_at":"2026-04-09T21:53:59+00:00","publisher_domain":"gstatic.com","signal_understanding":{"analysis_basis":"headline_and_summary","claim_confidence":0.62,"dates_mentioned":[],"entities":[{"asset_class":"equity","name":"Avalyn","relevance":"high","symbol":"","type":"company"},{"asset_class":"media","name":"FirstWord Pharma","relevance":"high","symbol":"","type":"publisher"}],"event_type":"listing","information_gaps":["The provided article text is not actually present (only CSS/HTML styling is included), so no verifiable details about the IPO (e.g., timing, exchange, offering size, underwriters, ticker) can be extracted.","The phrase \u201cinhaled lung disease hopefuls\u201d is not defined in the provided text; no other company names are available.","No confirmation is provided on whether Avalyn itself is the IPO issuer or whether it is associated with other \u201chopefuls.\u201d"],"key_facts":["Headline states that Avalyn and inhaled lung disease hopefuls have joined the IPO queue.","Source attributed to FirstWord Pharma."],"numeric_claims":[],"primary_claim":"Avalyn and its inhaled lung disease-focused hopefuls have joined the IPO queue, according to FirstWord Pharma.","relevance_score":0.45,"sentiment":"neutral","source_quality":"high","summary":"The signal indicates that Avalyn and companies developing inhaled lung disease therapies have entered the IPO pipeline, as reported by FirstWord Pharma. No additional IPO terms or company details are present in the provided text.","topics":["IPO queue","Avalyn","inhaled lung disease therapies","FirstWord Pharma"]},"source":"FirstWord Pharma","source_domain":"gstatic.com","summary":"Avalyn and its inhaled lung disease hopefuls join the IPO queue FirstWord Pharma","tickers":[],"title":"Avalyn and its inhaled lung disease hopefuls join the IPO queue - FirstWord Pharma","url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp"}... |